Colgate-Palmolive Company (NYSE:CL) Receives $94.38 Consensus Target Price from Brokerages

Colgate-Palmolive Company (NYSE:CL) has received an average recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $94.75.

A number of analysts have commented on the company. Jefferies Financial Group lifted their target price on Colgate-Palmolive from $85.00 to $91.00 and gave the stock a “hold” rating in a report on Monday, February 2nd. Barclays lifted their price objective on Colgate-Palmolive from $83.00 to $88.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Bank of America upped their target price on shares of Colgate-Palmolive from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. JPMorgan Chase & Co. lifted their price target on shares of Colgate-Palmolive from $93.00 to $97.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Finally, TD Cowen reissued a “buy” rating on shares of Colgate-Palmolive in a report on Monday, February 2nd.

Insider Transactions at Colgate-Palmolive

In other Colgate-Palmolive news, insider John Hazlin sold 20,989 shares of the business’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $94.25, for a total transaction of $1,978,213.25. Following the completion of the sale, the insider directly owned 17,645 shares in the company, valued at $1,663,041.25. The trade was a 54.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Stanley J. Sutula III sold 97,843 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $94.27, for a total transaction of $9,223,659.61. Following the completion of the transaction, the chief financial officer owned 55,310 shares in the company, valued at $5,214,073.70. This trade represents a 63.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 184,683 shares of company stock worth $17,486,693 in the last three months. 0.34% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC raised its holdings in Colgate-Palmolive by 4.4% in the 4th quarter. Brighton Jones LLC now owns 10,578 shares of the company’s stock worth $962,000 after purchasing an additional 450 shares during the period. Woodline Partners LP increased its position in Colgate-Palmolive by 76.3% in the first quarter. Woodline Partners LP now owns 46,361 shares of the company’s stock worth $4,344,000 after buying an additional 20,062 shares in the last quarter. Mutual Advisors LLC raised its stake in shares of Colgate-Palmolive by 5.1% in the second quarter. Mutual Advisors LLC now owns 8,265 shares of the company’s stock worth $727,000 after buying an additional 401 shares during the period. Stratos Wealth Advisors LLC purchased a new position in shares of Colgate-Palmolive during the 2nd quarter valued at about $262,000. Finally, Stanley Laman Group Ltd. grew its stake in shares of Colgate-Palmolive by 16.3% during the 2nd quarter. Stanley Laman Group Ltd. now owns 2,942 shares of the company’s stock valued at $267,000 after acquiring an additional 413 shares during the period. 80.41% of the stock is currently owned by institutional investors.

Colgate-Palmolive Stock Up 1.2%

Shares of Colgate-Palmolive stock opened at $95.07 on Monday. The company has a 50-day simple moving average of $85.61 and a two-hundred day simple moving average of $82.27. The stock has a market capitalization of $76.63 billion, a PE ratio of 36.29, a price-to-earnings-growth ratio of 4.24 and a beta of 0.29. Colgate-Palmolive has a 52-week low of $74.54 and a 52-week high of $100.18. The company has a debt-to-equity ratio of 5.90, a quick ratio of 0.27 and a current ratio of 0.42.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings results on Friday, January 30th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.04. The company had revenue of $5.23 billion during the quarter, compared to the consensus estimate of $5.13 billion. Colgate-Palmolive had a net margin of 10.45% and a return on equity of 353.72%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.91 earnings per share. On average, analysts anticipate that Colgate-Palmolive will post 3.75 EPS for the current fiscal year.

Colgate-Palmolive Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Wednesday, January 21st were issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, January 21st. Colgate-Palmolive’s dividend payout ratio is presently 79.39%.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.